Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac

Tanya J. Lehky, Michael C. Levin, Ryuji Kubota, Richard N. Bamford, Alfred N. Flerlage, Samantha S. Soldan, Thomas P. Leist, Andrew Xavier, Jeffrey D. White, Margaret Brown, Thomas A. Fleisher, Lois E. Top, Susan Light, Henry F. McFarland, Thomas A. Waldmann, Steven Jacobson

Research output: Contribution to journalArticle

Abstract

Human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurological disease that results from an interaction of retroviral infection and immune activation. In this study, five doses (1 mg/kg) of humanized anti-Tac antibody were administered to 9 HAM/TSP patients at weeks 0, 2, 6, 10, and 14. Preliminary immunological studies on HAM/TSP patients treated with humanized anti-Tac indicate that there is a selective down-regulation of activated T cells and a decrease in the HTLV-I viral load in peripheral blood lymphocytes, most likely through the selective removal of HTLV-I-infected, activated CD4+ lymphocytes.

Original languageEnglish (US)
Pages (from-to)942-947
Number of pages6
JournalAnnals of Neurology
Volume44
Issue number6
StatePublished - Dec 1998
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac'. Together they form a unique fingerprint.

  • Cite this

    Lehky, T. J., Levin, M. C., Kubota, R., Bamford, R. N., Flerlage, A. N., Soldan, S. S., Leist, T. P., Xavier, A., White, J. D., Brown, M., Fleisher, T. A., Top, L. E., Light, S., McFarland, H. F., Waldmann, T. A., & Jacobson, S. (1998). Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Annals of Neurology, 44(6), 942-947.